Opko Health Inc. (OPK) Expected to Announce Earnings of -$0.07 Per Share

Equities research analysts expect Opko Health Inc. (NASDAQ:OPK) to announce ($0.07) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Opko Health’s earnings, with estimates ranging from ($0.10) to ($0.03). Opko Health reported earnings of ($0.08) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The company is expected to report its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Opko Health will report full year earnings of ($0.20) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.06). For the next year, analysts forecast that the company will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.21) to $0.10. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The company had revenue of $221.90 million for the quarter, compared to analyst estimates of $242.05 million. Opko Health had a negative net margin of 15.46% and a negative return on equity of 7.69%.

Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Barrington Research restated a “buy” rating and set a $5.00 price target on shares of Opko Health in a research report on Thursday, February 28th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and a consensus price target of $9.67.

OPK stock traded down $0.01 during midday trading on Tuesday, hitting $2.40. 6,731,012 shares of the stock traded hands, compared to its average volume of 3,690,665. The firm has a market cap of $1.48 billion, a PE ratio of -9.60 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.96 and a current ratio of 1.10. Opko Health has a 1-year low of $2.34 and a 1-year high of $6.40.

In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were acquired at an average cost of $2.48 per share, with a total value of $496,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $7,610,998.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of the firm’s stock in a transaction on Thursday, January 31st. The shares were bought at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the acquisition, the insider now owns 24,455,147 shares of the company’s stock, valued at $194,662,970.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 798,000 shares of company stock worth $2,032,580. Insiders own 42.74% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Diversified Trust Co purchased a new position in Opko Health during the fourth quarter valued at $30,000. FDx Advisors Inc. purchased a new position in Opko Health during the fourth quarter valued at $33,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Opko Health in the first quarter worth about $39,000. Meeder Asset Management Inc. lifted its stake in shares of Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock worth $35,000 after buying an additional 4,846 shares in the last quarter. Finally, Douglas Lane & Associates LLC purchased a new position in shares of Opko Health in the fourth quarter worth about $42,000. 23.10% of the stock is currently owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Story: What is the float in trading stocks?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.